News zum Sektor Gesundheit aus Norwegen

 

Oslo, 4 July Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 1 July 2025, regarding the board of directors' resolution to increase the share capital of the Company by the issuance of 6,000,000 new shares to Jiangsu Hongxin Medical Technology Co. Ltd ("Jiangsu") in connection with the private placement, at a subscription price of NOK 0.50 per share (the "Jiangsu Conversion Shares") through set-off against a receivable amounting to NOK 3,000,000 that Jiangsu had against the Company (following transfer...

An extraordinary general meeting in Oncoinvent ASA will be held on 4. August 2025 at  12:00 CEST. The meeting will be held in Gullhaugveien 7, Oslo with the possibility for a virtual participation. The formal call will be sent to all shareholders registered in the Norwegian Central Security Depository (VPS). The complete set of documents and link relating to the extraordinary general meeting will be made available on www.oncoinvent.com/investors/general-meetings. Shareholders are recommended to exercise their shareholder rights through completing the proxy form with voting instruction....

Oslo, 3 July 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 12 June 2025, regarding notice of an extraordinary general meeting in connection with, inter alia, a private placement (including a loan conversion to be completed by Navamedic ASA) and a contemplated subsequent offering in the Company. The extraordinary general meeting was held today, on 3 July 2025, at 14:00 hours (CEST). All resolutions proposed by the Company's board of directors were approved, including (i) the issuance of 56,...

Oslo, 3 July 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 11 June 2025 regarding the successfully placed private placement (the "Private Placement") of 72,890,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.50 per Offer Share for gross proceeds totalling NOK 36,445,000. As stated in the announcement, the completion of the Private Placement was, inter alia, subject to the extraordinary general meeting of the Company (the "EGM") resolving to increase the...

Bergen, Norway – 3 July 2025: BerGenBio ASA (OSE:BGBIO) will hold an Extraordinary General Meeting virtually on 4 August 2025 at 12:00 PM (CEST).   The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments are available on the Company's website: https://www.bergenbio.com/investors/general-meetings/   All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor Services, by using...

Oslo, 3 July 2025: On the basis of the approval by the General Meeting on 29 April 2025 to authorize the Board of Directors of Zelluna ASA (the 'Company', OSE ticker “ZLNA”) to grant new shares to employees and board members under a long-term incentive program, the Board of Directors has resolved to issue share options to all employees in the Company....

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES. Helsinki, Finland, 2 July 2025: Reference is made to the stock exchange announcement on 26 June 2025, where Nordhealth AS (the "Company") launched an offer to purchase up to 300,000 of its own shares through a reverse book building process (the "Offering"). The application period expired at 16:30 hours (CEST) on 2 July 2025. Following the end of the application...

12-month readout of the HeROPA phase 2b clinical trial shows potential through key secondary endpoint PGA 0/1, where the per protocol population approaches significance (p = 0.07) after one year of treatment. Relevant subgroups show statistical significance (p < 0.05). Importantly, HRO350 was well tolerated throughout the study, with no safety concerns or drug-related serious adverse events reported. While the primary endpoint (PASI50 at 26 weeks) in the 52-week placebo-controlled study was not met due to an unexpectedly high placebo response, the overall data support the potential of...

Oslo, 1 July 2025 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker "OBSVR") is pleased to announce the strengthening of its strategic partnership with its key manufacturing partner, Jiangsu Hongxin Medical Technology Co. Ltd ("Jiangsu"), through Jiangsu's subscription for 6,000,000 shares in the Company. This agreement not only solidifies our collaboration but also delivers a significant positive liquidity effect, freeing up capital to accelerate the commercial rollout of UnoMeter. Reference is furhter made to the stock exchange announcement by Observe Medical ASA (...

Oslo, 1 July 2025 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker "OBSVR") is pleased to announce the strengthening of its strategic partnership with its key manufacturing partner, Jiangsu Hongxin Medical Technology Co. Ltd ("Jiangsu"), through Jiangsu's subscription for 6,000,000 shares in the Company. This agreement not only solidifies our collaboration but also delivers a significant positive liquidity effect, freeing up capital to accelerate the commercial rollout of UnoMeter. Reference is furthter made to the stock exchange announcement by Observe Medical ASA (...

Oslo, 1 July 2025 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 27 June 2025, regarding, inter alia, the resolution of the annual general meeting to reduce the Company's share capital by way of reducing the nominal value of each share with NOK 3.48, from NOK 3.90 to NOK 0.42. The share capital reduction has today been registered in the Norwegian Register of Business Enterprises, and the Company's new share capital is NOK 8,088,533.04, divided into 19,258,412 shares, each with a nominal value of...

Bergen, Norway and Oslo, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the......

OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the......

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Bergen, 30 June 2025: Reference is made to the stock exchange announcement published by BerGenBio ASA (the "Company") earlier today,...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Oslo, 29 June 2025 - Reference is made to the stock exchange announcement made by Navamedic ASA (the "Company" or "Navamedic", and...

Genetic Analysis AS' (“GA” or the “Company”) subsequent offering to existing shareholders, for which the subscription period ended on June 16, 2025 (the "Subsequent Offering"), has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret). During the period June 5 – June 16, 2025, GA carried out the Subsequent Offering that provided the Company with approximately NOK 4.1 million by issuance of 4,813,194 new shares, before issue costs. The Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises. After this, the...

OSLO, Norway, June 27, 2025 /PRNewswire/ -- Navamedic announces that the Swedish Medical Products Agency, acting as the Reference Member State, together with the Concerned Member States in 9 additional countries have approved OraFID® for use with a medicinal product. "OraFID® is a unique,......

Oslo, 27 June 2025 The annual general meeting of Observe Medical ASA (the "Company" or "Observe Medical", Euronext Expand ticker "OBSRV") was held today, on 27 June 2025 at 10:00 hours (CEST), at Dronning Eufemias gate 16, 2nd floor, 0191 Oslo, Norway. All resolutions were made in accordance with the proposals from the board of directors and the nomination committee. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com. As set out in the minutes, the general meeting has resolved to reduce the Company's share capital by way...

Oslo, June 24, 2025 – Observe Medical ("the Company" or "Observe Medical") is pleased to announce that UnoMeter[TM] Safeti[TM] Plus has been appointed exclusive winner of the tender in the largest region in Sweden, representing approximately 20% of the total Swedish market. In Finland UnoMeter[TM] Safeti[TM] has been awarded the tender for Helsinki and Tampere which represents approx. 20% of the Finnish market, on a non-exclusive basis. In Denmark supply contracts has been signed and deliveries have commenced to 3 out of 5 healthcare regions, representing nearly 60% of the national market....

Bergen, 26 June 2025: BerGenBio ASA held its annual general meeting today digitally through Lumi AGM. All resolutions were made in accordance with the proposals from the board of directors and the nomination committee, including, but not limited to, approval of the 2024 annual accounts, election of a member to and the remuneration the board of directors and nomination committee. The minutes from the annual general meeting are attached hereto and will also be made available on the company's website www.bergenbio.no.   For further information, please contact: Olav Hellebø, CEO,...